Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 5,860,000 shares, an increase of 19.3% from the October 15th total of 4,910,000 shares. Based on an average daily volume of 504,200 shares, the days-to-cover ratio is currently 11.6 days. Approximately 13.3% of the shares of the company are short sold.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS traded down $0.09 during trading hours on Friday, reaching $4.19. The stock had a trading volume of 793,622 shares, compared to its average volume of 750,478. The business’s fifty day moving average is $3.69 and its two-hundred day moving average is $3.65. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Sell-side analysts expect that Pyxis Oncology will post -1.03 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently added to or reduced their stakes in PYXS. Fullcircle Wealth LLC bought a new position in Pyxis Oncology during the second quarter valued at $40,000. Intech Investment Management LLC purchased a new position in Pyxis Oncology in the 3rd quarter valued at $55,000. SG Americas Securities LLC purchased a new position in Pyxis Oncology in the third quarter worth approximately $58,000. The Manufacturers Life Insurance Company acquired a new position in shares of Pyxis Oncology in the second quarter valued at approximately $65,000. Finally, MetLife Investment Management LLC increased its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Analyst Upgrades and Downgrades

PYXS has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, Stephens assumed coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Pyxis Oncology has a consensus rating of “Buy” and an average price target of $9.57.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.